
|Videos|October 11, 2016
Promising Alzheimer Antibody-Based Immunotherapy
Author(s)Bobby Lazzara, MD
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Advertisement
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
3
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
4
CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis
5










